RxSight chief business development officer Eric Weinberg sells $14,205 in stock By Investing.com

Eric Weinberg, Chief Business Development Officer at RxSight, Inc. (), recently sold 2,041 shares of the company’s common stock for a total value of $14,205. The shares were sold at a price of $6.96 per share on September 2, 2026. This transaction was specifically executed to cover tax withholding obligations in connection with the vesting of restricted stock units and does not represent a discretionary sale by Mr. Weinberg. The stock currently trades at $7.03, down 32.5% year-to-date despite the company maintaining more cash than debt on its balance sheet. According to InvestingPro analysis, RXST appears undervalued at current levels, with the stock trading below its Fair Value. Investors can access the comprehensive Pro Research Report for deeper insights into RXST’s valuation and growth prospects.

Prior to this sale, on August 31, 2026, Mr. Weinberg acquired 5,370 shares of common stock. These shares were received upon the vesting of restricted stock units (RSUs), with an acquisition price of $0. Each RSU represents a contingent right to receive one share of RxSight’s common stock. These RSUs are subject to a vesting schedule, with portions vesting on specific dates through February 28, 2029, provided Mr. Weinberg continues as a service provider.

Following these transactions, Mr. Weinberg directly beneficially owns 200,348 shares of RxSight common stock. This total includes 1,668 shares acquired on October 31, 2025, under the company’s 2021 Employee Stock Purchase Plan. Additionally, Mr. Weinberg indirectly holds 299,978 shares through the EJW Living Trust, for which he serves as trustee, and 925 shares are held indirectly by his spouse.

In other recent news, RxSight reported second-quarter 2026 results that exceeded Wall Street expectations. The company posted an adjusted earnings loss of $0.11 per share, surpassing the anticipated loss of $0.36. Revenue also came in strong at $33.74 million, above the forecast of $32.21 million. Despite these positive results, RxSight withdrew its full-year guidance, citing ongoing challenges in its core business. This decision led to a decrease in after-hours trading. Additionally, Stifel adjusted its price target for RxSight to $7.00 from $8.00, maintaining a Hold rating. The adjustment was made due to competitive pressures, although Stifel noted that recent trends have shown improvement. These developments highlight the ongoing challenges and adjustments faced by RxSight in the current market environment.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.